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Abstract 
The mitochondrial H+-ATP synthase is a bottleneck component in the provision of 
metabolic energy by oxidative phosphorylation. The expression of its catalytic subunit (β-F1-
ATPase) is stringently controlled at post-transcriptional levels during oncogenesis, the cell cycle 
and in development. Here we show that miR-127-5p targets the 3’UTR of β-F1-ATPase mRNA 
(β-mRNA) significantly reducing its translational efficiency without affecting β-mRNA 
abundance. Despite the reduced expression of β-F1-ATPase in most human carcinomas, we 
observed no expression of miR-127-5p in different human cancer cell lines, minimizing the 
potential role of miR-127-5p as a regulator of the bioenergetic activity of mitochondria in 
cancer. In contrast, miR-127-5p is highly over-expressed in the human fetal liver. Consistent 
with previous findings in the rat, the expression of β-F1-ATPase in the human liver also seems 
to be controlled at post-transcriptional levels during development, what might suggest a role for 
miR-127-5p in controlling β-mRNA translation and thus in defining the bioenergetic activity of 
human liver mitochondria. Moreover, immunolocalization techniques and subcellular 
fractionation experiments using different antibodies against β-F1-ATPase reveal that the ectopic 
expression of β-F1-ATPase at the cell surface of the hepatocytes and HepG2 cells is negligible 
or stands for scrutiny. 
Keywords: Mitochondria, H+-ATP synthase, Liver, Translational control, Human development, 
Pathology 
Abbreviations: β-, α- and γ-F1-ATPase: subunits β, α and γ of the mitochondrial H+-ATP 
synthase; β- and γ-mRNA: mRNAs of subunits β- and γ-F1-ATPase; G3BP1: Ras-GAP SH3 
binding protein 1; GFP: green fluorescent protein; SDH-B: succinate dehydrogenase subunit B; 
3’UTR: 3’ untranslated region; ERRγ and ERRα: estrogen receptor gamma and alpha 
transcription factors; PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator 1-
alpha; ATP5B: β-F1-ATPase gene. 
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1. Introduction 
Mitochondrial activity provides the energy required for adaptation to distinct 
environmental and physiological conditions of the organism. The mitochondrial H+-ATP 
synthase is the engine used for ATP production by oxidative phosphorylation [1]. Previous 
studies in yeast and mammalian tissues have shown that the expression of the catalytic subunit 
of the H+-ATP synthase (β-F1-ATPase), which is encoded in the nuclear genome, is mainly 
regulated by post-transcriptional mechanisms that affect mRNA localization, stability and 
translation [2-6]. In particular, during development of rat liver [2, 7], in brown adipose tissue [8] 
and in rat [4] and human [9] carcinomas the expression of β-F1-ATPase is regulated at the level 
of translation.  Mechanistically, both during development and in oncogenesis β-F1-ATPase 
mRNA (β-mRNA) translation is masked by specific factors that hinder ribosome recruitment 
onto the mRNA [2, 4, 10, 11]. In this regard, an important cis-acting element required for β-
mRNA translation is the 3’UTR of the transcript [2-6]. The 3’UTR of β-mRNA acts as a 
translational enhancer both in vitro [2, 9, 12] and in vivo [13], and is essential for the 
localization [5, 6] and efficient translation of the transcript [2, 9].  
Post-transcriptional control of the expression of specific mRNAs can be explained by 
the binding of regulatory proteins and/or miRNAs to cis-acting elements of the mRNA. 
Recently, Ras-GAP SH3 binding protein 1 (G3BP1) has been shown to interact with the 3’UTR 
of β-mRNA to inhibit the initiation step of translation [11] contributing in this way to the 
observed down-regulation of β-F1-ATPase expression in cancer. On the other hand, miRNAs 
are important post-transcriptional regulators of gene expression [14]. miRNAs are short, 
approximately 22-nucleotides long RNAs, that are transcribed as a long primary transcript that 
folds into a hairpin structure. After nuclear processing, the ~70 nucleotide precursor miRNA 
(pre-miRNA) is exported to the cytoplasm and processed by Dicer into miRNA duplexes. One 
strand of the duplex represents the mature miRNA that has to be incorporated into a miRNA-
induced silencing complex (RISC) to exert its biological function [14]. miRNAs regulate 
various biological processes including developmental timing, cell fate determination, apoptosis 
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and metabolism [15-17]. Changes in the expression of miRNAs are associated with human 
pathology including cancer [14, 18-21]. Animal miRNAs regulate gene expression by 
imperfectly base pairing to the 3’-UTR of target mRNAs inhibiting protein synthesis or 
inducing the degradation of the targeted mRNA [22]. However, it has also been reported that 
some miRNAs can induce translation of the target mRNA [23-25].  
Due to the relevant implication of β-F1-ATPase in cell biology and in human pathology 
[10, 26] the aim of this study was to identify miRNAs that might be involved in post-
transcriptional control of β-F1-ATPase expression.  For this purpose we generated stable cell 
lines expressing GFP fused to the 3’UTR of human β-mRNA and searched for potential miRNA 
that can modify the fluorescence intensity of the cells. We show that β-mRNA is specifically 
targeted and translationally silenced by miR-127-5p. We report that miR-127-5p is highly 
expressed in human fetal liver and show that β-F1-ATPase expression is post-transcriptionally 
regulated during human liver development. We suggest that miR-127-5p might play a relevant 
role in controlling the bioenergetic phenotype of the hepatocyte during human development.  
Moreover, we have estimated that the content of β-F1-ATPase at the plasma membrane of 
human and rat hepatocytes and HepG2 cells is insignificant as assessed by conventional 
immunological techniques with validated antibodies. 
2. Material and methods  
2.1 Plasmids and cloning strategies. The plasmids expressing a hybrid GFP fused in 
frame with the mitochondrial targeting sequence of β-F1-ATPase (pβ) [27] containing either the 
3’UTR of human β-mRNA (pβGFP-3´βh, pIW22) or α-F1-ATPase mRNA (α-mRNA) (pβGFP-
3´αh, pIW23) were cloned as described [9]. The plasmid pβ-GFP-3’βMUT (pIW29) contains 
four point mutations in the 3’UTR seed sequence of the hsa-miR-127-5p binding site of β-
mRNA. To introduce the mutations, two overlapping PCR products containing the desired 
mutations were amplified using oligos F-preβ-EGFP-KpnI: 5′-
GCGGGTACCCGAATCCAGTCTC-3′/R-3’hBmut-PCR1a: 5’-
 5
CACAGAAAAATAAGGGTCTTTGGGTTAGG-3’ and F-3'β-h-EcoRI: 5’-
GCGGAATTCGGGGTCTTTGTCCTCTGTA-3’ / F-3’hBmut-PCR1b: 5’-
CCTAACCCAAAGACCCTTATTTTTCTGTG-3’. The PCR products were mixed 1:1, 
incubated for 5 min at 94°C and 30 min at 37°C to allow annealing of complementary tails. To 
form one full length mutated PCR fragment, 1.75 mM dNTPs and 1 U/µl of Klenow DNA 
polymerase were added and incubated for 30 min at 37°C. The product from this reaction was 
used as a template for a second PCR reaction using the outer primers F-3'β-h-EcoRI: 5’-
GCGGAATTCGGGGTCTTTGTCCTCTGTA-3’ and R-3'β-h-XhoI: 5’-
GCGCTCGAGTTTTTTTTTTTTTGAGGGGTGTA-3’. The amplified PCR fragment was 
purified, digested with EcoRI and XhoI and cloned into the pβGFP-3’Δ plasmid [9].  
2.2 Cell cultures, generation of GFP expressing cells and transfection of plasmids 
and miRNAs. The human BT549 breast and HepG2 liver cancer cell lines were grown in RPMI 
and DMEM respectively, supplemented with 10% FBS, 400 μM non-essential amino acids, 1 
mM glutamine, 100 UI/ml penicillin and 0.1mg/ml streptomycine. Cells were transfected with 
plasmids pβGFP-3´αh or pβGFP-3´βh using Lipofectamine and Plus reagent (Invitrogen). After 
24 h of transfection cells were split 1:10 and 1:20 into 10 cm plates and grown in the 
appropriate medium containing 0.3 mg/ml geneticin (G418, GIBCO). After 1-2 weeks isolated 
colonies began to appear and the drug-resistant GFP-fluorescent clones were isolated with 
cloning cylinders and sub-cloned into 96-well plates. The clones were expanded and the purity 
of the cell population analyzed by flow cytometry. miRNAs were transfected at the time of 
plating using siPORT NeoFx reagent (Ambion/Applied Biosystems). The medium was changed 
at 24 h post-transfection and the cells were analyzed at 48 h post-transfection. miRNAs were 
used at a final concentration 30 nM. The pre- and anti-miRNAs used in this study were 
purchased from Ambion/Applied Biosystems and were PM11164 (pre-miRNA hsa-miR-423-
5p), PM11414 (pre miRNA hsa-miR-101), PM13001 (pre-miRNA hsa-miR-127-5p), PM11646 
(pre-miRNA hsa-miR-581), PM10492 (pre-miRNA hsa-miR-200b), PM11753 (pre-miRNA 
hsa-miR-186), PM10632 (pre-miRNA hsa-miR-103), AM11164 (anti-miRNA hsa-miR-423-
 6
5p), AM11646 (anti-miRNA hsa-miR-581), AM10492 (anti-miRNA hsa-miR-200b), AM11753 
(anti-miRNA hsa-miR-186), AM10632 (anti-miRNA hsa-miR-103), AM13001 (anti-miRNA 
hsa-miR-127-5p) and AM17110 (miRNA negative control #1). Co-transfection of miR-127-5p 
and the plasmids pβ-GFP-3’βMUT or pβ-GFP-3’β were performed in a 1:1 molar ratio using 
Lipofectamine and Plus reagent (Invitrogen). In all cases the cell culture was incubated with the 
cationic-lipid-DNA complexes for 2 h at 37°C.  
2.3 Flow cytometry. After 48 h of transfection cellular pellets were resuspended in 
200-400 µl FACS solution (1% FBS, 0.1% NaN3 and 1xPBS) and analyzed by flow cytometry. 
The fluorescence intensity of at least 10,000 events was determined in a FACScan cytometer 
(Becton-Dickinson) using CellQuest (Becton-Dickinson) acquisition software. The results were 
analyzed with the program FlowJo (TreeStar). 
2.4 Screening of potential miRNAs by fluorescence reporter assays. Over-
expression and silencing assays of the selected miRNAs were performed in BT549 clones stably 
expressing a mitochondrial localized GFP fused to the 3’UTR of β-F1-ATPase mRNA 
(BT549:pβGFP-3’β) using the indicated miRNAs precursors (pre-miRNA), anti-miRNAs and 
miRNA negative control #1. As an additional control of the screening experiments BT549 
clones stably expressing a mitochondrial localized GFP fused to the 3’UTR of α-F1-ATPase 
mRNA (BT549:pβGFP-3’α) were studied in parallel. The assays were carried out in 96-well 
plates with a black border and a clear flat bottom (Corning). After 48 h of transfection the cells 
were stained for 10 min at 37°C with 5µg/ml of Hoescht (Sigma) diluted in cell culture medium 
without phenol red. The fluorescence intensity of Hoescht (excitation: 340-10nm, emission: 
470-10nm) and of GFP (excitation: 485nm, emission: 510-10nm) was determined using a 
FLUOstar Omega Microplate Reader (BMG Labtech). The fluorescence intensity of GFP was 
normalized by the number of cells as determined by Hoechst fluorescence intensity and 
quantified relative to the cells transfected with a non-relevant miRNA (control). 
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2.5 Cloning, expression and purification of γ-F1-ATPase and antibody production. 
The cDNA (BC000931) encoding human γ-F1-ATPase (AAH35198) was amplified by PCR 
using the LGC-Promochem MGC-5380 clone and primers 5’-cgcgagctcatgttctctcgcgcg-3’ and 
5’-atagtttagcggccgcatccagagctgctgc-3’ which add SacI and NotI restriction sites, respectively. 
The resulting product was purified and first cloned into pGEM-Teasy vector (Promega) and 
after into pQE-Trisystem [28]. The resulting plasmid, pQE-γF1, that encodes γ-F1-ATPase with 
C-terminal 6xHis and streptavidin tags, was used to transform E.coli BL-21 cells. Protein 
expression was induced by addition of 1mM IPTG. After overnight induction, the cells were 
collected and the expressed protein purified using Ni-NTA superflow resin (Qiagen) [28]. To 
produce monoclonal antibodies against human γ-F1-ATPase, we proceeded as recently 
described [28]. In brief, BALB/c mice were immunized with various doses of the purified 
protein (20 µg) and the hybridomas produced by fusing spleen cells with the SP2 myelomas. 
Supernatants of the hybridomas were screened by indirect ELISA on γ-F1-ATPase-coated 
polystyrene plates. Bound antibodies were detected using horseradish-peroxidase-labeled goat 
anti-mouse antibodies (1:1,000 DAKO). The positive colonies were cloned by limiting dilution. 
Mouse monoclonal antibodies were purified with Montage antibody purification kit (Millipore) 
and used at a 1:1000 dilution.  
2.6 Quantification of miRNA and mRNA. RNA was extracted from cell cultures 
using TRIzol Reagent (Invitrogen). Human fetal (20-44 weeks, #636540 from Clontech and 
A601605 and A604419 from BioChain) and adult (51-64 year-old men, #636531 from Clontech 
and B510061 and B510092 from BioChain) total liver RNA were purchased. The expression 
level of mature miRNAs was determined using TaqMan MicroRNA Assay from Applied 
Biosystems, which includes a unique set of RT-PCR primers and a specific TaqMan probe. 
RNA was reverse transcribed using the TaqMan MicroRNA Reverse Transcription Kit (Applied 
Biosystems). The TaqMan MicroRNA Assays used in this study were RNU48 (#001006, 
Applied Biosystems), U6 snRNA (#001973, Applied Biosystems) and hsa-miR-127-5p 
(#002229, Applied Biosystems). The qPCR reaction was performed as indicated by the supplier 
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using 2X Universal Master Mix without UNG (Applied Biosystems) and an ABI PRISM 7900 
SDS thermocycler. Expression of miR-127-5p was determined according to the ΔΔCt method 
using RNU48 (cell lines) or U6 (human samples) as internal controls, respectively. 
Quantification of β-mRNA, γ-F1-ATPase and succinate dehydrogenase subunit B (SDH-B) 
mRNAs and 18S rRNA expression in human liver samples by RT-PCR was performed as 
described [9, 11]. 
2.7 Protein extraction and Western blotting. For protein extraction, cellular pellets 
were resuspended in lysis buffer (25 mM Hepes, 2.5 mM EDTA, 1% Triton X-100, 1 mM 
PMSF and 5 μg/mL leupeptin) supplemented with complete protease inhibitor cocktail EDTA-
free (Roche). Cell lysates were clarified by centrifugation at 10000 × g for 7 min. Adult human 
liver samples were obtained from the Banco de Tejidos y Tumores, IDIBAPS, Hospital Clinic, 
Barcelona, Spain, coded for anonymity [29]. The Institutional Review Board approved the 
project. Fetal human liver lysates were purchased from ProSci Incorporated (#XBL-10409), 
Abcam (ab29890) and BioChain (A605254). Protein concentrations were determined with the 
Bradford reagent (Bio-Rad Protein Assay). Protein extracts were fractionated on SDS-PAGE 
and transferred onto PVDF membranes for immunoblot analysis. The primary monoclonal 
antibodies used were: anti-Hsp60 (Stressgene SPA-807, 1:5000), anti-GFP (Clontech, 1:10000), 
anti-β-actin (Sigma, 1:100000), anti-γ-F1-ATPase (1:1000), anti-E-cadherin (BD Pharmigen, 
1:1000) and anti-SDH-B (Molecular Probes, 1:500), anti-β-F1-ATPase (Ab1) (Molecular 
Probes, 1:1000) and the polyclonal rabbit anti-β-F1-ATPase (Ab2) (1:15000) [29] and (Ab3) 
[30]. Peroxidase-conjugated anti-mouse or anti-rabbit IgGs (Nordic Immunonology, 1:5000) 
were used as secondary antibodies. The blots were developed using the ECL reagent 
(Invitrogen). 
2.8 Immunohistochemistry. Paraffin-embedded human liver 5 μm tissue sections were 
stained using a diaminobenzidine-based method using the Envision-Plus-horseradish peroxide 
system (DAKO) as detailed [29]. The dilution of the anti-β-F1-ATPase (Ab2) used was 1:3000. 
Nuclei were counterstained with hematoxylin.  
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2.9 Electron microscopy. Small pieces (~ 1mm3) of rat liver samples were fixed by 
immersion in freshly prepared 4% paraformaldehyde in 0.1 M Sörensen phosphate buffer, pH 
7.2 and supplemented with 6 % sucrose, for 2 h at 4ºC. Samples were rinsed in buffer and the 
free-aldehyde groups were quenched with 50 mM ammonium chloride in PBS for 60 min at 
4ºC. Afterwards, the samples were rinsed in PBS, dehydrated in acetone and finally processed 
for embedding in Lowicryl K4M (Polysciences Europe, Eppelheim, Germany) according to 
manufacturer’s instructions. Gold interferential color ultrathin sections were collected in 
collodion/carbon-coated nickel grids. For the immunocytochemical localization of β-F1-
ATPase, the grids were incubated with a 1:50 dilution of anti-β-F1-ATPase (Ab3) [30]. After 
three washes with PBS, grids were incubated for 45 min with Protein A-gold complex (10 nm). 
Fixation was carried out with 1% glutaraldehyde in PBS. Counterstaining was performed with 
2% uranyl acetate (7 min) and 1% lead citrate (45 s). The grids were observed in a Jeol 1010 
electron microscope under 80 kV accelerating voltage. 
2.10 Immunofluorescence. For double-immunofluorescence microscopy HepG2 cells 
were grown on coverslips and fixed with 2 % paraformaldehyde in PBS for 30 min. Cellular 
permeabilization was achieved by incubation with 0.1 % Triton X-100 for 10 min. Coverslips 
were first incubated in 1 % FCS in PBS for 10 min and washed before incubation with the 
primary monoclonal anti-β-catenin (BD Pharmingen, 1:100) and the polyclonal anti-β-F1-
ATPase (Ab2) antibodies. After, coverslips were incubated for 1h in the dark with goat-anti 
rabbit IgGs conjugated to Alexa 594 and goat anti-mouse IgGs conjugated to Alexa 488. 
Cellular staining was analyzed in a confocal microscope Biorad Radiance 2000 Zeiss Axiovert 
S100TV. 
2.11 Purification of mitochondria and plasma membranes. Rat liver homogenates 
were prepared in a solution containing 0.25 M sucrose, 1 mM EGTA and 10 mM Tris-HCl pH 
7.4 and centrifuged at 800g for 10 min to remove nuclei and unbroken cells. The resulting post-
nuclear supernatants (H) were fractionated on 35 ml sucrose density gradients [24-54 % (w/v)]. 
The gradients were centrifuged at 145,000g for 70 min at 4ºC. Fractions were collected from the 
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bottom of the tube and the localization of mitochondria (Mi) performed by western blotting 
using antibodies against β-F1-ATPase and Hsp60. Liver post-nuclear supernatants (H) were 
centrifuged first at 8,500g for 10 min and the resulting supernatants were further centrifuged at 
180,000g for 1h. The resulting microsomal pellet was homogenized in 20 ml of 57 % sucrose 
and placed on the bottom of the centrifuge tube. Thirty ml of 34 % sucrose was added on top of 
the microsomal sample. The discontinuous gradient was centrifuged at 54,000g for 16h at 4ºC. 
Fractions were collected from the bottom of the tube and the localization of the plasma 
membrane (PM) fraction performed by western blotting using antibodies against E-cadherin 
(BD Pharmingen, 1:1000). 
2.13 Statistical Analysis. Statistical analyses were performed using a two-tailed 
Student’s t-test. The results shown are means ± SEM. A p < 0.05 was considered statistically 
significant. 
 
 
3. Results 
3.1 Potential miRNAs targeting the 3’UTR of human β-mRNA. In order to identify 
potential miRNAs that could bind the 3’UTR of human β-mRNA we performed a bioinformatic 
study using the miRNA target prediction software TargetScan5.1 (http://www.targetscan.org/). 
The TargetScan prediction algorithm is based on few binding rules [31-33]. In brief, the most 
important requirement seems to be a contiguous and perfect Watson-Crick base pairing of the 
5’-miRNAs ”seed” region. Matching of the mRNA to the miRNA seed can be divided into 
8mer-, 7mer- and 6mer-sites. An A residue at position 1 (7mer-A1) and an A or U at position 9 
of the miRNA improves miRNA activity [33]. In addition, miRNAs that are conserved among 
different species are preferentially selected. Following these binding rules and with the purpose 
of covering the entire length of the 3’UTR of β-mRNA we selected miR-101, miR-127-5p, 
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miR-186, miR-200b, miR-423-5p and miR-581 as the strongest candidates from the in silico 
results (Fig. 1A). miR-103 was also included in the study because of the putative relevance that 
hypoxia [34] might have in regulating β-F1-ATPase expression, even though miR-103 does not 
fit to the above mentioned rules.  
3.2 miR-127-5p is a potential regulator of β-F1-ATPase expression. For screening 
purposes, and in order to analyze the influence of miRNAs on the expression of β-F1-ATPase in 
breast cancer cells, we generated BT549 cell lines that stably express a mitochondrial targeted 
GFP reporter bearing the 3’UTR of β-mRNA (Fig. 1B). The pre-sequence of β-F1-ATPase (pβ) 
was fused in frame upstream of the GFP coding region to localize the reporter protein into 
mitochondria [27] because this cis-acting element of β-mRNA is also required for the 
appropriate subcellular localization of the mRNA [6]. To assess the specificity of the action of 
the selected miRNAs on the 3’UTR of β-mRNA we also developed BT549 cell lines stably 
expressing the same reporter but containing the 3’UTR of α-F1-ATPase mRNA (α-mRNA) 
(Fig. 1C) which is a counterpart subunit of β-F1-ATPase in the mitochondrial H+-ATP synthase 
[1].  After generation of the stable cell lines both the pβGFP-3’α and pβGFP-3’β expressing 
cells were analyzed by flow cytometry to analyze the purity of the clones as well as their GFP 
fluorescence intensity.  The analysis showed that the selected pβGFP-3’β (β2 and β10 in Fig. 
1B) and pβGFP-3’α (α2 and α4 in Fig. 1C) clones exhibited a well-defined and single peak of 
high-intensity GFP fluorescence (> 103 a.u.), indicating a very high degree of purity (> 98%).  
The red traces in Fig. 1B and 1C show the background of the fluorescence signal of wild type 
cells (100-101 a.u.). Therefore, shifts in the fluorescence intensity of the generated clones can be 
taken as indicative of interfering GFP expression by the effect of the transfected miRNA 
precursor molecules (pre-miRNAs), which are designed to directly enter the miRNA processing 
pathway and mimic endogenous miRNAs in the cells. Moreover, all the clones targeted GFP to 
mitochondria as revealed by the co-localization of GFP fluorescence with Mitotracker Red by 
confocal microscopy (Figs. 1B and 1C).  
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In order to identify which of the selected miRNAs might be relevant in controlling β-
F1-ATPase expression we first carried out miRNA over-expression experiments using miRNA 
precursors (pre-miRNA) in the GFP-tagged cells. The relative activity of the miRNAs targeting 
the 3’UTR of β-mRNA was assessed by determining the relative GFP fluorescence intensity of 
pβGFP-3’β clones when compared to that of pβGFP-3’α clones (Fig. 2A). The study revealed 
that from all the miRNAs analyzed only miR-127-5p triggered a significant decrease in GFP 
fluorescence in both pβGFP-3’β clones (β2 and β10 in Fig. 2A) when compared to pβGFP-3’α 
clones (α4 in Fig. 2A) and cells transfected with a non-relevant miRNA (control in Fig. 2A). 
Western blot analysis of pβGFP-3’β2 cells confirmed a reduced expression of the GFP reporter 
when cells were treated with miR-127-5p (Fig. 2B). Notably, silencing experiments using the 
corresponding anti-miRNAs, including anti-miR-127-5p, revealed that none of them had a 
relevant effect on the fluorescence intensity (Fig. 2C) and GFP expression (Fig. 2D) of pβGFP-
3’β clones when compared to controls. 
3.3 β-mRNA is targeted and silenced by miR-127-5p. Next, we questioned about the 
activity of miR-127-5p on the expression of the endogenous β-F1-ATPase. Transfection of miR-
127-5p precursors in parental BT549 cells provoked a significant decrease in the expression of 
β-F1-ATPase protein (Fig. 3A, histogram to the left). In this situation, the cellular content of β-
mRNA was not affected when compared to control cells that were transfected with a non 
relevant miRNA (Fig. 3A, histogram to the right).  Consistent with the above mentioned 
findings (Fig. 2C,D) the transfection of BT549 cells with anti-miR-127-5p had no effect on β-
F1-ATPase expression (Fig. 3B), suggesting that BT549 breast cancer cells do not express 
significant levels of miR-127-5p. The determination of miR127-5p expression in BT549 and 
other cancer cell lines confirmed the lack of expression of this miRNA in these cells (see Fig. 
5A), raising the question of what is the physiological context where miR127-5p might be of 
relevance in controlling the expression of human β-F1-ATPase. Anyway, the negative effect of 
miR-127-5p on β-F1-ATPase expression was further underlined by the observation that the 
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expression of β-F1-ATPase was restored to that of control cells when miR-127-5p expression 
was silenced by co-transfection with anti-miR-127-5p (Fig. 3B).  
To verify that the down-regulation of β-F1-ATPase expression is due to the targeting of 
miR-127-5p to its presumed binding site on the 3’UTR of β-mRNA we generated a mutated 
version of the pβGFP-3’β expression plasmid (pβGFP-3’βMUT) that contains four point 
mutations on the miR-127-5p binding region (Fig. 4A). Preliminary experiments indicated that 
the fluorescence intensity of pβGFP-3’βMUT expressing cells was not significantly affected by 
the co-expression of miR-127-5p (1.00 versus 0.96 arbitrary units in the absence or presence of 
miR-127-5p, respectively). Analysis of GFP fluorescence in BT549 cells co-transfected with the 
miR-127-5p precursor and pβGFP-3’β or pβGFP-3’βMUT plasmids revealed that whereas miR-
127-5p significantly inhibited GFP fluorescence derived from the pβGFP-3’β plasmid the 
expression of GFP derived from the mutated plasmid was not affected (Fig. 4A). These findings 
were further confirmed by western blot analysis (Fig. 4B), that illustrated a very sharp reduction 
of GFP expression derived from the pβGFP-3’β plasmid whereas GFP expression was not 
affected from the pβGFP-3’βMUT expressing cells. It should be noted that over-expression of 
miR-127-5p promoted in both pβGFP-3’β and pβGFP-3’βMUT expressing cells a significant 
reduction of the endogenous β-F1-ATPase (Figs. 4B). Taken together, these results illustrate 
that miR-127-5p targets the 3’UTR of human β-mRNA and interferes with translation of the 
transcript. 
It appears that western blots are more sensitive than fluorescence analysis to illustrate 
the activity of a particular miRNA (compare differences in GFP expression between Fig. 4B and 
4A). Since this situation raised the possibility that other of the miRNAs studied in this work 
(Fig. 2A) could have some effect on β-F1-ATPase expression, presumably with less activity 
than miR-127-5p, we also verified the activity of the miRNAs by western blotting (Fig. 4C). 
The results obtained confirmed the data of the fluorescence study (Fig. 2A), i.e., only miR-127-
5p has relevant activity as regulator of the expression of β-F1-ATPase (Fig. 4C).  
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3.4 miR-127-5p is expressed in human liver but not in cancer cells. To identify in 
which physiological context miR-127-5p could affect β-F1-ATPase expression we first 
analyzed by RT-qPCR its expression in several human cancer cell lines. The results obtained 
revealed that breast (BT549 and T47D), colon (HCT116), lung  (Hop62), HeLa and Jurkat 
cancer cells do not express significant levels of miR-127-5p (Fig. 5A), most likely indicating 
that miR-127-5p does not play a role in silencing β-mRNA translation in these carcinomas. In 
contrast, human fetal liver samples expressed highly significant levels of miR-127-5p when 
compared to adult livers (Fig. 5A), suggesting that it might play a role in controlling β-F1-
ATPase expression in the human liver during development. Interestingly, the expression of 
proteins involved in energy metabolism, such as subunits β-F1-ATPase and γ-F1-ATPase of the 
mitochondrial H+-ATP synthase and of subunit B of succinate dehydrogenase (SDH-B) are 
barely detectable in fetal liver extracts but show a remarkable increase in their expression in the 
adult liver (Fig. 5B). In contrast, it should be noted that the expression of the structural 
mitochondrial protein Hsp60 did not show significant differences between fetal and adult liver 
extracts (Fig. 5B). Therefore, the β-F1-ATPase/Hsp60 ratio increased significantly during 
development of the human liver (Fig. 5B), in agreement with previous results in rat liver that 
illustrated the rapid postnatal biogenesis and functional differentiation of mammalian 
mitochondria [7, 35-37]. Consistent with the relevance of translational control for the 
biosynthesis of β-F1-ATPase observed in lower mammals [36], we noted that liver mRNA 
levels for both the β and γ subunits of the H+-ATP synthase as well as of SDH-B showed no 
relevant changes during development (Fig. 5C), i.e., the mRNAs are represented at the time of 
development when the amount of the proteins is very limited. This was not the situation for the 
liver content of Hsp60 where both mRNA (Fig. 5C) and protein (Fig. 5B) levels correlated.  
3.5  β-F1-ATPase is not expressed at the plasma membrane of the hepatocytes. It has been 
reported that β-F1-ATPase is a high-density lipoprotein (HDL) receptor for apolipoprotein A-I 
localized on the plasma membrane of rat and human hepatocytes and HepG2 cells [38]. To find 
out the fraction that plasma membrane β-F1-ATPase might represent from the total cellular 
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content of the protein we have studied the expression and localization of β-F1-ATPase in rat and 
human liver as well as in HepG2 cells using different experimental techniques and antibodies 
(Ab1, Ab2 and Ab3) (Fig. 6). Immunohistochemistry of paraffin-embedded human liver 
sections using a polyclonal antibody against β-F1-ATPase (Ab2) [29] revealed no 
immunoreactive material on the plasma membrane of the hepatocytes whereas a strong labeling 
of cytoplasmic organelles was observed (Fig. 6A). High-resolution immunoelectron microscopy 
of rat liver thin sections, using a different antibody (Ab3) [30], showed a strong gold decoration 
of mitochondria of the hepatocytes in the absence of plasma membrane recognition of any 
immunoreactive material (arrows in Fig. 6B). Double-immunofluorescence microscopy of non-
permeabilized HepG2 cells using an antibody against β-catenin, a plasma membrane protein 
(green, Fig. 6C) and anti-β-F1-ATPase (Ab2) (red, Fig. 6C) showed the almost complete 
absence of β-F1-ATPase on the plasma membrane. The only red signals appeared decorating the 
mitochondria of the few cells (< 10 %) that are inevitably permeabilized as a result of the 
fixation procedure (arrow in Fig. 6C). Similar findings were obtained using a commercially 
available antibody against β-F1-ATPase (Ab1) (data not shown). As expected, both Ab2 (Fig. 
6D) and Ab1 (data not shown) specifically recognized mitochondria in permeabilized HepG2 
cells. Altogether, we show that various cellular fixation procedures and localization techniques 
using different antibodies against β-F1-ATPase only recognized immunoreactive material in 
mitochondria supporting the marginal presence of β-F1-ATPase at the plasma membrane of 
mammalian liver cells. 
 Furthermore, rat liver homogenates were prepared and the mitochondria and plasma 
membrane fractions purified (Fig. 6E). Western blotting of proteins from these fractions using 
specific antibodies against mitochondria (Hsp60 and β-F1-ATPase) and plasma membrane (E-
cadherin) markers, confirmed the enrichment of mitochondria (compare H versus Mi in Fig. 6E) 
and plasma membranes (compare H versus PM in Fig. 6E) in their respective fractions. 
Remarkably, none of the three antibodies used against β-F1-ATPase recognized a band in the 
plasma membrane fractions (Fig. 6E). Similar negative findings have been obtained using a 
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monoclonal anti-β-F1-ATPase (data not shown) developed recently [39]. These results also 
support that there is no ectopic expression of β-F1-ATPase on the cell surface of liver cells or, 
alternatively, that the content of β-F1-ATPase in the plasma membrane is negligible when 
considered the total cell content of the protein. Therefore, and for the rest of this work, we will 
not take into consideration the contribution that the plasma membrane protein could have in this 
study. 
 
4. Discussion 
The control of β-F1-ATPase expression is essential for normal cell function. In fact, 
down-regulation of its expression is linked to cancer progression [10, 29, 40] or to the onset of a 
small group of devastating rare diseases [26]. In the present study we have investigated the role 
that miRNAs could play in controlling β-F1-ATPase expression in humans and the likely 
physiological context where they might exert their function. This is part of an ongoing project 
aimed at the characterization of the post-transcriptional mechanisms involved in the regulation 
of β-F1-ATPase expression in human pathophysiology [4, 10, 11]. Initially, we intended to 
characterize the mechanism of repression of β-F1-ATPase expression in breast cancer [9]. 
Therefore, the BT549 breast cancer cell line was selected for developing the GFP-3’β and GFP-
3’α clones because it is a cell line that shows an intermediate expression level of β-F1-ATPase 
when compared to other breast cancer cells of the NCI panel (T47D, MDA-N > BT5490 = 
HS578T > MCF7, ADR-RES, MDA-231, MDA-435). Of the seven miRNAs studied we found 
that only miR-127-5p functionally interferes with β-F1-ATPase expression. Moreover, it was 
further found that this miRNA is not expressed in many cancer cells. This unexpected finding 
promoted the search for other physiological contexts where miR-127-5p might play a role in 
regulating the translation of β-mRNA and found its likely participation in development of the 
liver. A recent report identified miR-101 as a post-transcriptional regulator of β-F1-ATPase 
expression in HeLa cells [41]. Our fluorescence and western blot data in BT549 cells does not 
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support such a role for miR-101 perhaps due to differences in the cells studied. In general, 
miRNAs silence gene expression by induction of mRNA degradation or by inhibition of its 
translation [22, 42-44]. We illustrate that expression of miR-127-5p brings about a profound 
decrease in the steady state level of the endogenous β-F1-ATPase without affecting β-mRNA 
levels. Moreover, we show that miR-127-5p specifically targets the 3’UTR of the transcript. 
These results indicate that the mechanism of action of miR-127-5p on β-F1-ATPase expression 
is exerted by repressing β-mRNA translation.  
In the mouse miR-127 is expressed in embryos, placenta and post-natal brain and 
muscle [45] as well as in fetal lung [46]. It is expressed as a part of a cluster with miR-136, 
miR-431, miR-432, and miR-433 both in normal tissues and cultured fibroblasts of mouse and 
humans [45, 47]. The expression of the cluster and specifically of miR-127 is down-regulated in 
primary tumors and various cancer cell lines [47]. Moreover, the miR-127 promoter is 
embedded in a CpG island and remains methylated in most tissues except sperm [47]. Treatment 
of cancer cells with chromatin-modifying drugs promoted the up-regulation of miR-127 which 
targets the mRNA of the protooncogene BCL6 to inhibit its expression [47]. Consistent with 
these findings, miR-127 is over-expressed in diffuse large B-cell lymphomas [48] and Epstein-
Bar virus (EBV) positive Burkitt lymphomas [49], supporting that miR-127 acts as a potential 
tumor suppressor by blocking terminal differentiation of B-cells and hence favoring their 
proliferation [47-49]. A role for miR-127 has been suggested in the control of cellular 
differentiation because it is preferentially expressed in the mesenchymal rather than in the 
epithelial compartment of the lung towards the end of fetal stages of development [46]. In fact, 
over-expression of miR-127 in fetal lung cultures impedes normal lung differentiation [46]. 
Consistent with these findings we report that miR-127-5p is highly over-expressed in the fetal 
liver. Hence, we suggest that miR-127-5p does not play a role in controlling β-F1-ATPase 
expression in oncogenesis and thus in promoting the down-regulation of the protein that 
accompanies the bioenergetic switch during cellular transformation [10, 40] but rather it 
represses the differentiation of mitochondria during fetal liver development [35].  
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Cancer cells and embryonic tissues display large phenotypic similarities regarding the 
molecular and functional activities of mitochondria [37, 50]. In fact, fetal hepatocytes and 
hepatocarcinomas are highly glycolytic cells because both the number and the bioenergetic 
activity of their mitochondria are very low [35, 37, 50]. Consistent with the observations in 
lower mammals recent reports demonstrated that the activity of oxidative phosphorylation 
complexes increases significantly in liver, brain, muscle and heart of humans after birth [51, 
52]. The analogies also affect the mechanisms that control the expression of genes of the H+-
ATP synthase because β-mRNA is accumulated in a translation repressed state in fetal rat liver 
[2, 7, 36], in rat hepatocarcinomas [4] and in human lung, colon and breast carcinomas [9]. 
Accumulation of β-mRNA in developing liver and in rat carcinomas is accounted for by 
controlling the rate of turnover of the transcript [4, 36]. The storage of masked β-mRNA in the 
fetal liver and its rapid translational activation immediately after birth [2, 7, 36] is required to 
promote the functional differentiation of liver mitochondria [35] allowing adaptation of 
mammals to the aerobic environment. In agreement with these findings our study illustrates that 
subunits β and γ of the H+-ATP synthase are hardly expressed in human fetal liver boosting their 
expression in the adult liver. Paradoxically, and consistent with findings in rat liver [36], we 
observed no differences in steady state β-mRNA levels in the human liver during development 
strongly suggesting that the low content of β-F1-ATPase in humans also results from translation 
silencing of the corresponding mRNA. Similar paradoxical findings were obtained for the 
counterpart γ-F1-ATPase subunit. The mechanisms that control the translation of β-mRNA are 
very complex [10] and, in addition to miR-127-5p, β-F1-ATPase expression is also regulated by 
specific RNA-binding proteins such as G3BP1 that also targets the 3’UTR of the transcript [11]. 
In this scenario, we suggest that protein- and RNA-mediated mechanisms that regulate the 
interaction of essential cis-acting elements of β-mRNA with the translational machinery are of 
upmost importance to unveil β-F1-ATPase expression in different physiological contexts [10]. 
Importantly, the β-F1-ATPase/Hsp60 ratio, which illustrates the energetic competence of 
mitochondria [29], showed a significant increase after birth.  This finding indicates that human 
fetal liver mitochondria are deficient in the molecular components of the H+-ATP synthase and 
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perhaps in mitochondrial functionality, resembling very much the findings obtained in lower 
mammals [37, 50]. Within this context, miR-127-5p might be of physiological relevance to 
regulate the attenuation of β-mRNA translation during development of the human fetal liver.  
Remarkably, the promoter of human miR-127 gene can be activated by estrogen related 
receptor gamma (ERRγ) and alpha (ERRα) transcription factors [53]. Functional and 
biochemical studies have shown that ERRα is involved in energy metabolism and mitochondrial 
biogenesis [54]. Together with PGC-1α, ERRα is involved in the induction of the ATP5B gene 
that encodes β-F1-ATPase [55, 56]. Thus, one can speculate that during fetal stages of human 
liver development ERRα simultaneously activates the transcription of β-F1-ATPase and of miR-
127-5p, the repressor of β-mRNA translation. This could promote the accumulation of masked 
β-mRNA in the fetal liver ensuring a less functionality of the H+-ATP synthase to allow an 
active glycolysis which is the main pathway of the proliferating hepatocyte [40]. It is likely that 
the targeting of miR-127-5p to its presumed binding site in  the 3’UTR of β-mRNA is an 
assisted process exerted in co-operation with the RNABPs that built the human β-RNP [11, 21]. 
Post-translational modification of any of these proteins [21] by the cellular signaling events that 
occur in mammals after birth [57] might induce the release of miR-127-5p from β-mRNA to 
allow its effective translation and the functional differentiation of human liver mitochondria. 
Within this context, miR-127-5p could function in human liver development in a similar way to 
that of miR-378* in cancer, which has been shown to be an important regulator of the 
bioenergetic switch experienced in breast cancer for adjusting the cell to a changing metabolic 
demand [58].  
Taken together, our results indicate that translational control of β-mRNA is also 
operative during human liver development. Since miR-127-5p is highly expressed in the fetal 
human liver and targets the 3’UTR of β-mRNA repressing its translation we suggest that it 
offers a potential candidate for controlling the expression of β-F1-ATPase during development 
and therefore in regulating the bioenergetic differentiation of human liver mitochondria.  
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5. Conclusion 
miR-127-5p targets the 3’UTR of β-F1-ATPase mRNA (β-mRNA) and inhibits its 
translation without affecting β-mRNA abundance. The expression of β-F1-ATPase is controlled 
at the level of translation during development of the human liver. Since miR-127-5p is highly 
expressed in the fetal human liver we suggest that it might be involved in defining the 
bioenergetic activity of mitochondria in the hepatocyte during development.   
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Figure legends 
Figure 1. Tools for the identification of miRNAs targeting the 3’UTR of human β-mRNA. 
A, Schematic illustration of the 3’UTR of human β-mRNA and of the miRNAs predicted to 
bind the 3’UTR with higher affinity (TargetScan). Binding sites and types of the miRNAs 
selected are indicated in color code. The hypoxia regulated miR-103 (light green) was also 
included in the study for the putative relevance that hypoxia might play in regulating β-F1-
ATPase expression. Generation and analysis of the BT549:pβGFP-3’β (B) and BT549:pβGFP-
3’α (C) cell lines used to screen the activity of miRNAs. Graphs in B and C illustrate the GFP 
fluorescence of BT549 clones that express mitochondria-targeted GFP fused to the 3’UTR of 
human β-mRNA (clone β2, orange and β10, blue) or to the 3’UTR of α-mRNA (clone α2, 
magenta and α4, blue), respectively. The percentage of GFP expressing cells is indicated. The 
basal cellular fluorescence of the parental wild type (WT) BT549 cells is shown in red trace. 
Representative immunofluorescence examples of the targeting of GFP (green) to 
MitotrackerRed stained mitochondria (red) in BT549:pβGFP-3’β (B) and BT549:pβGFP-3’α 
(C) cells.  
Figure 2. Fluorescence reporter assays identify miR-127-5p as a potential regulator of β-
F1-ATPase expression. A, The GFP fluorescence intensity of two BT549 cell clones (β2 in 
yellow and β10 in green) expressing pβGFP-3’β was determined after 48 h of transfection with 
the indicated miRNAs precursors using a fluorescence luminometer. Data were normalized 
relative to the number of cells as determined by Hoescht fluorescence intensity and quantified 
relative to the mean GFP fluorescence of control cells transfected with a non-relevant miRNA 
(control). The fluorescence intensity of BT549 cells expressing pβGFP-3´α (α4 in black) was 
also analyzed as an additional control of the screening. The results shown are the means ± SEM 
of three independent experiments. *, p< 0.0001 when compared to pβGFP-3´α by Student’s t-
test. B, Western blot analysis of GFP expression in total cell lysates of BT549:pβGFP-3’β2 cells 
non-transfected (NTF) or transfected with pre-miR-127-5p (miR-127-5p) or a scramble miRNA 
(control). The GFP/β-actin ratio is indicated. C, Fluorescence reporter assays using anti-
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miRNAs. The GFP fluorescence intensity of two BT549 cell clones (β2 in yellow and β10 in 
green) expressing pβGFP-3’β was determined after 48 h of transfection. Data were normalized 
as indicated in A. The fluorescence intensity of BT549 cells expressing pβGFP-3´α (α4 in 
black) was also analyzed as an additional control of the screening. The results shown are the 
means ± SEM of three independent experiments. D, Western blot analysis of GFP expression in 
total cell lysates of BT549:pβGFP-3’β2 cells non-transfected (NTF) or transfected with anti-
miR-127-5p or a scramble miRNA (control). The GFP/β-actin ratio is indicated. 
Figure 3. miR-127-5p inhibits the translation of β-mRNA. A, Western blot analysis of the 
expression of β-F1-ATPase in total cell lysates (histogram to the right) and RT-qPCR 
quantification of β-mRNA (histogram to the left) of BT549 cells transfected with miR-127-5p 
precursor (miR-127-5p, open bars) or a scramble miRNA (control, closed bars). Lanes 1 and 2 
correspond to two different experiments of the same experimental condition. The results shown 
are the mean±SEM of three independent experiments. The quantification of β-F1-ATPase 
expression is indicated using β-actin as reference protein. *, p<0.001 when compared to control 
by Student’s t-test. B, Analysis of β-F1-ATPase expression in BT549 cells transfected with 
miR-127-5p precursor (open bar), anti-miR-127-5p (gray bar), both miR-127-5p precursor + 
anti-miR-127-5p (hatched bar) or a negative control miRNA (control, closed bar). The 
quantification of β-F1-ATPase expression is indicated using Hsp60 as reference protein. The 
results shown are the means ± SEM of four independent experiments. *, p<0.05 when compared 
to control by Student’s t-test.  
Figure 4. miR-127-5p specifically targets the 3’UTR of human β-mRNA. A, Schematic 
illustration of the four point mutations (in red, asterisks) introduced in the 3’UTR of β-mRNA 
to generate the pβ-GFP-3βMUT plasmid (3βMUT). On top, the miR-127-5p (green) seed 
matching sequence on the 3’UTR of β-mRNA is indicated (highlighted in gray). The histogram 
shows the fluorescence intensity of BT549 cells co-transfected with miR-127-5p or a negative 
control miRNA (control) and reporter plasmids expressing GFP fused either to the 3’UTR of β-
mRNA (3’β) (open and closed bars) or  to the mutant 3’UTR of β-mRNA (gray bar, 3’βMUT). 
 27
The results shown are the mean ± SEM of three independent experiments. *, p<0.001 when 
compared to control by Student’s t-test. B, Western blot analysis in total cell lysates of BT549 
cells co-transfected with miR-127-5p precursor (lanes 1-4) or a negative control miRNA 
(control, closed bar) (lanes 5 and 6) and the reporter plasmids expressing GFP fused to the wild 
type 3’β (open bar) (lanes 1 and 2) and control (lanes 5 and 6) or mutant (3’βMUT, gray bar) 
(lanes 3 and 4) 3’UTR of β-mRNA. Two different experiments assayed in the same gel for each 
condition are shown. The lower histogram shows β-F1-ATPase (β-F1) expression relative to 
that of β-actin. The results shown are the mean ± SEM of four experiments.  *, p<0.005 when 
compared to control by Student’s t-test. Note the lack of effect of miR-127-5p on GFP 
expression derived from the 3’βMUT and the silencing of the endogenous β-F1-ATPase.  C, 
Western blot analysis of β-F1-ATPase (β-F1) expression in BT549 cells transfected with the 
indicated miRNAs precursors or a scramble miRNA (control). The β-F1/β-actin ratio is 
indicated. 
Figure 5. miR-127-5p is expressed in fetal human liver. A, Quantification of miR-127-5p 
expression by RT-qPCR in human cancer cell lines (BT549, T47D, HCT116, Hop62, Jurkat and 
HeLa) and in fetal and adult human liver. miR-127-5p expression in the cell lines and during 
liver development was normalized to RNU48 and U6 RNA, respectively. The results shown are 
the mean ± SEM of three experiments.  *, p<0.005 when compared to fetal by Student’s t-test. 
B, Western blot analysis of the expression of the mitochondrial proteins Hsp60, β-F1-ATPase 
(β-F1), γ-F1-ATPase (γ-F1) and subunit B of succinate dehydrogenase (SDH-B) in human fetal 
and adult liver extracts. The expression of β-actin was used as reference of protein loading. 
Lanes 1 and 2 under the same heading correspond to two different fetal or adult liver extracts. 
The histogram summarizes the relative expression level of each protein in adult liver extracts 
(open bars) relative to the level observed in fetal extracts (closed bars). The β-F1-
ATPase/Hsp60 ratio is also shown. The results shown are the mean ± SEM of three different 
extracts.*, p<0.01 when compared to fetal by Student’s t-test. C, RT-qPCR analysis of β-F1-
ATPase mRNA, γ-F1-ATPase mRNA, SDH-B mRNA and Hsp60 mRNA in fetal (closed bars) 
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and adult (open bars) human liver samples. Data were normalized relative to 18S rRNA and are 
shown as fold change relative to the values in fetal liver. The results shown are the mean ± SEM 
of three different samples.  
Figure 6. No evidence for the localization of β-F1-ATPase at the plasma membrane. A, 
Immunohistochemical characterization of the expression of β-F1-ATPase in human liver 
sections using a polyclonal anti-β-F1-ATPase (Ab2) only reveals the mitochondrial localization 
of the protein. B, High-resolution immunoelectron microscopy of rat liver ultrathin sections 
processed with a polyclonal anti-β-F1-ATPase (Ab3) reveals the specific labeling (10 nm gold, 
white stripes) of mitochondria (m) in the absence of gold decoration of the plasma membrane 
(arrows) of the hepatocyte. C, Double immunofluorescence microscopy of non-permeabilized 
HepG2 cells with anti-β-catenin (green) and anti-β-F1-ATPase (Ab2) (red) reveals non-relevant 
immunolabeling of β-F1-ATPase on the plasma membrane. The only red signals observed (β-
F1-ATPase) are confined to cytoplasmic organelles in few partially permeabilized cells as a 
result of the fixation procedure (arrow). D, Double immunofluorescence microscopy of 
permeabilized HepG2 cells reveals the almost complete absence of β-catenin signal (green). The 
strong red signals of the β-F1-ATPase antibody (Ab2) are confined to cytoplasmic organelles. 
E, Western blotting of rat liver postnuclear supernatants (H), purified mitochondria (Mi) and 
plasma membrane (PM) proteins using three different antibodies against the β-subunit of the 
H+-ATP synthase (Ab1, Ab2 and Ab3). Probing of the membranes with anti-hsp 60 and anti-E-
cadherin, markers of mitochondria and plasma membrane, respectively, confirmed the 
enrichment of mitochondria and plasma membranes in their respective fractions. The blots show 
no immunoreactivity against β-F1-ATPase at the PM fraction. 
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